Audentes Therapeutics Inc (BOLD) Rating Lowered to Sell at Zacks Investment Research
Audentes Therapeutics Inc (NASDAQ:BOLD) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday.
According to Zacks, “Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company’s product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. “
A number of other equities analysts have also recently issued reports on the stock. Piper Jaffray Cos. began coverage on shares of Audentes Therapeutics in a research note on Monday, August 15th. They issued an “overweight” rating and a $24.00 price objective for the company. Wedbush began coverage on shares of Audentes Therapeutics in a report on Monday, August 15th. They issued an “outperform” rating and a $20.00 target price on the stock. Finally, Cowen and Company began coverage on shares of Audentes Therapeutics in a report on Monday, August 15th. They issued an “outperform” rating on the stock.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/audentes-therapeutics-inc-bold-rating-lowered-to-sell-at-zacks-investment-research.html
Audentes Therapeutics (NASDAQ:BOLD) traded up 1.53% during mid-day trading on Wednesday, hitting $19.25. 40,026 shares of the company were exchanged. The stock’s market cap is $418.21 million. Audentes Therapeutics has a 12-month low of $13.06 and a 12-month high of $20.42. The company has a 50 day moving average of $15.91 and a 200 day moving average of $15.51.
In related news, insider James E. Flynn acquired 400,000 shares of the firm’s stock in a transaction on Monday, July 25th. The shares were purchased at an average price of $15.00 per share, with a total value of $6,000,000.00. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Orbimed Advisors Llc acquired 33,334 shares of the firm’s stock in a transaction on Monday, July 25th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $500,010.00. The disclosure for this purchase can be found here.
About Audentes Therapeutics
Audentes Therapeutics, Inc is a biotechnology company. The Company focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects. Its portfolio of product candidates include AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Audentes Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.